Heinrich Kovar

List of Publications by Year
in descending order

57	7,094	101535	155644
papers	citations	36 h-index	55 g-index

61	61	61	6498
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature, 1992, 359, 162-165.	27.8	1,724
2	MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer, 1991, 67, 1886-1893.	4.1	627
3	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. Journal of Clinical Oncology, 2015, 33, 3036-3046.	1.6	516
4	Ewing sarcoma. Nature Reviews Disease Primers, 2018, 4, 5.	30.5	500
5	Ewing's Sarcoma Family of Tumors: Current Management. Oncologist, 2006, 11, 503-519.	3.7	424
6	EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5324-5329.	7.1	260
7	DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nature Medicine, 2017, 23, 386-395.	30.7	193
8	Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1. Cell Reports, 2015, 10, 1082-1095.	6.4	183
9	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nature Genetics, 2012, 44, 323-327.	21.4	160
10	A Molecular Function Map of Ewing's Sarcoma. PLoS ONE, 2009, 4, e5415.	2.5	158
11	Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene, 1997, 15, 2225-2232.	5.9	134
12	Caveolin-1 (CAV1) Is a Target of EWS/FLI-1 and a Key Determinant of the Oncogenic Phenotype and Tumorigenicity of Ewing's Sarcoma Cells. Cancer Research, 2006, 66, 9937-9947.	0.9	126
13	Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Human Pathology, 2012, 43, 1300-1307.	2.0	119
14	Dr. Jekyll and Mr. Hyde: The Two Faces of the FUS/EWS/TAF15 Protein Family. Sarcoma, 2011, 2011, 1-13.	1.3	110
15	Ewing Sarcomaâ€"Diagnosis, Treatment, Clinical Challenges and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 1685.	2.4	101
16	Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Research, 2013, 23, 1797-1809.	5.5	99
17	Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. ELife, 2017, 6, .	6.0	94
18	EWS-FLI1 Suppresses NOTCH-Activated p53 in Ewing's Sarcoma. Cancer Research, 2008, 68, 7100-7109.	0.9	90

#	Article	IF	Citations
19	Context matters: The hen or egg problem in Ewing's sarcoma. Seminars in Cancer Biology, 2005, 15, 189-196.	9.6	87
20	EwingÊ¼s sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. Current Opinion in Oncology, 1998, 10, 334-342.	2.4	85
21	EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene, 2005, 24, 2512-2524.	5.9	85
22	Detection of tumour cells in peripheral blood and bone marrow from ewing tumour patients by rt-pcr. International Journal of Cancer, 1995, 64, 135-139.	5.1	81
23	Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells. Blood, 2012, 120, 5199-5208.	1.4	81
24	Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget, 2017, 8, 34141-34163.	1.8	72
25	Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma. Cancer Research, 2014, 74, 6578-6588.	0.9	66
26	The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis. Cells, 2020, 9, 972.	4.1	66
27	Hypoxia Modulates EWS-FLI1 Transcriptional Signature and Enhances the Malignant Properties of Ewing's Sarcoma Cells In vitro. Cancer Research, 2010, 70, 4015-4023.	0.9	65
28	Intercohort Gene Expression Co-Analysis Reveals Chemokine Receptors as Prognostic Indicators in Ewing's Sarcoma. Clinical Cancer Research, 2010, 16, 3769-3778.	7.0	58
29	Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. Epigenetics, 2014, 9, 1613-1625.	2.7	55
30	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624.	1.8	55
31	Downstream EWS/FLI1 - upstream Ewing's sarcoma. Genome Medicine, 2010, 2, 8.	8.2	53
32	Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Expert Opinion on Therapeutic Targets, 2014, 18, 1315-1328.	3.4	53
33	The Ewing family of tumors and the search for the Achillesâ€™ heel. Current Opinion in Oncology, 1999, 11, 275.	2.4	52
34	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. Nature Communications, 2018, 9, 3184.	12.8	50
35	Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Cancer Research, 2002, 62, 4583-7.	0.9	47
36	EWS-FLI1 employs an E2F switch to drive target gene expression. Nucleic Acids Research, 2015, 43, 2780-2789.	14.5	39

#	Article	IF	Citations
37	Mechanisms, Diagnosis and Treatment of Bone Metastases. Cells, 2021, 10, 2944.	4.1	37
38	EWSâ€“FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. Nucleic Acids Research, 2019, 47, 9619-9636.	14.5	35
39	YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. Oncogenesis, 2021, 10, 2.	4.9	32
40	Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma. Journal of Pathology, 2011, 225, 353-363.	4.5	28
41	YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget, 2015, 6, 37678-37694.	1.8	24
42	EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. Oncotarget, 2017, 8, 24679-24693.	1.8	20
43	NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Kiâ€1 positive anaplastic large cell lymphomas. British Journal of Haematology, 1996, 92, 866-871.	2.5	18
44	Combinatorial Drug Screening Identifies Ewing Sarcomaâ€“specific Sensitivities. Molecular Cancer Therapeutics, 2017, 16, 88-101.	4.1	17
45	ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. Cell Reports, 2019, 29, 104-117.e4.	6.4	16
46	High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. Gene, 2017, 596, 137-146.	2.2	13
47	The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma. Oncotarget, 2017, 8, 10980-10993.	1.8	13
48	C/EBPÎ²-1 promotes transformation and chemoresistance in Ewing sarcoma cells. Oncotarget, 2017, 8, 26013-26026.	1.8	12
49	EWSâ€FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway. FEBS Letters, 2016, 590, 2063-2075.	2.8	11
50	Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers. Oncotarget, 2018, 9, 31018-31031.	1.8	10
51	Selective enhancer changes in osteosarcoma lung metastasis. Nature Medicine, 2018, 24, 126-127.	30.7	8
52	Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. PLoS ONE, 2020, 15, e0237792.	2.5	6
53	AURKA inhibitors: Right in time. Pediatric Blood and Cancer, 2010, 55, 3-4.	1.5	5
54	Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis. Cells, 2022, 11, 1267.	4.1	5

#	Article	IF	Citations
55	SLFN11: Achilles' Heel or Troublemaker. Clinical Cancer Research, 2015, 21, 4033-4034.	7.0	0
56	Ewing Sarcoma. , 2015, , 1655-1658.		0
57	Ewing Sarcoma. , 2015, , 1-4.		0